Investment Rating - The report does not provide a specific investment rating for the industry Core Insights - The Namibia Essential Medicines List (NEMList) is a critical document for ensuring the availability and accessibility of essential medicines in Namibia, aimed at improving public health outcomes [10][12][19] - The seventh edition of the NEMList reflects updates based on current clinical evidence, morbidity patterns, and treatment standards, ensuring that it remains relevant to the healthcare needs of the population [13][30] - A total of 298 items were deleted from the NEMList, including 41 antineoplastics, to align with the Standard Treatment Guidelines (STGs) focused on primary healthcare [31][32] - The introduction of the NiMART category replaces the previous IMAI-R category, allowing for better management of antiretroviral therapy at designated health facilities [32][56] Summary by Sections How to Use the Seventh Edition of the NEMList - The NEMList contains essential pharmaceutical items selected to meet the healthcare needs of the Namibian population at an affordable cost [29] - The document is structured to facilitate easy navigation and understanding of the essential medicines available [34][35] Restricted Use Classification - The NEMList includes categories for Restricted Use (R) and NiMART items, which require specific control measures and monitoring to prevent misuse [56][60] - NiMART items are available at designated health centers and require trained staff for their administration [56][58] The Namibian Essential Medicines List - The NEMList is organized according to therapeutic groups, allowing healthcare providers to easily identify necessary medications [67] - Each medicine is classified based on its availability and importance, guiding procurement and prescribing practices [21][24] Annexes - The annexes provide forms and guidelines for requesting changes to the NEMList and STGs, streamlining the process for healthcare professionals [25][54]

Submitted NDA for Anaphylm™ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of Anaphylm, subject to FDA approvalCompany to host investor call on May 13, 2025, at 8:00am ET WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives t ...